In this opening segment, Dr. Sagar Lonial welcomes the audience and frames the discussion around the evolving management of smoldering multiple myeloma, before asking the panel how they currently approach risk stratification in clinical practice.
Back
Smoldering Multiple Myeloma: Risk Stratification and Evidence Informing Early Therapeutic Strategies
In this discussion, experts will focus on the evolving management of smoldering multiple myeloma, with emphasis on how advances in risk stratification are influencing clinical decision-making. We will review the evidence for early therapeutic intervention versus active monitoring, drawing from recent clinical trials and guideline recommendations. The experts will also address practical considerations for applying these data in real-world practice, including patient selection, safety, and implications for long-term treatment sequencing, with the goal of providing a balanced, evidence-based perspective on patient care.
Smoldering Multiple Myeloma: Risk Stratification and Evidence Informing Early Therapeutic Strategies
Episodes
All
All
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss the clinical utility of the IMWG 20/2/20 model in risk stratification for smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss how emerging approaches such as genomic profiling and longitudinal risk assessment may help refine risk stratification in smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks the panel to comment on emerging data presented at recent ASH meetings examining circulating tumor cells as a potential biomarker in smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks Dr. Vincent Rajkumar how clinicians decide between continued observation and early intervention once a patient is classified as having high-risk smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks the panel to reflect on how the treatment landscape has evolved for smoldering multiple myeloma and why early therapeutic intervention is increasingly being discussed for selected high-risk patients.
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss the clinical implications of the AQUILA trial, which evaluated daratumumab monotherapy compared with active monitoring in patients with high-risk smoldering multiple myeloma.
In this segment, Dr. Sagar Lonial asks the panel to discuss the potential risks and benefits of early intervention in smoldering multiple myeloma, particularly given that many patients remain asymptomatic for extended periods.
In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss emerging data evaluating combination treatment strategies in smoldering multiple myeloma. The conversation focuses on studies exploring anti-CD38 antibodies combined with immunomodulatory agents, as well as data involving alternative anti-CD38 therapies such as isatuximab.
In this segment, Dr. Sagar Lonial asks the panel to discuss how early treatment strategies may influence future therapy options if patients with smoldering multiple myeloma eventually progress to active disease.
In this segment, Dr. Sagar Lonial asks the panel to discuss real world challenges that may limit the use of early treatment strategies in patients with high risk smoldering multiple myeloma.
In this closing segment, Dr. Sagar Lonial asks the panel to reflect on the most important unanswered questions that remain in smoldering multiple myeloma research and what evidence is still needed before early treatment strategies are more broadly adopted.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5